Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1991 Mar 15;88(6):2351–2355. doi: 10.1073/pnas.88.6.2351

Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.

B Calabretta 1, R B Sims 1, M Valtieri 1, D Caracciolo 1, C Szczylik 1, D Venturelli 1, M Ratajczak 1, M Beran 1, A M Gewirtz 1
PMCID: PMC51229  PMID: 2006173

Abstract

The c-myb protooncogene is preferentially expressed in hematopoietic cells, and its encoded protein, Myb, is required for hematopoietic cell proliferation. To analyze the relative Myb dependence of normal and leukemic human hematopoietic progenitor cells, normal bone marrow cells, several types of leukemic blast cells, and 1:1 mixtures of normal and leukemic cells were cultured in the presence of c-myb sense or antisense oligodeoxynucleotides; cell viability and cloning efficiency were then assessed. c-myb sense oligomers had negligible effects on normal and leukemic cells. In contrast, c-myb antisense oligomers strongly inhibited or completely abolished clonogenic growth of a T-cell leukemia line, 78% (18 of 23) of primary acute myelogenous leukemia cases examined, and 4 of 5 primary chronic myelogenous leukemia (CML) cases in blast crisis. In three of the latter patients, polymerase chain reaction analysis of a 1:1 mixture of c-myb antisense-treated normal and CML cells revealed a complete absence of bcr-abl expression, suggesting that the CML clonogenic units had been completely eliminated from the cultures. At antisense doses that inhibited leukemic cell growth, normal hematopoietic progenitor cells survived. Thus, normal and leukemic hematopoietic cells show differential sensitivity to the toxic effects of c-myb antisense DNA. Perturbation of c-myb function with antisense oligodeoxynucleotides might eventually form the basis for a molecular approach to leukemia therapy, perhaps most immediately as ex vivo bone marrow purging agents.

Full text

PDF
2351

Images in this article

2353Image
on p.2353
2354Image
on p.2354

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anfossi G., Gewirtz A. M., Calabretta B. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc Natl Acad Sci U S A. 1989 May;86(9):3379–3383. doi: 10.1073/pnas.86.9.3379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Auber M. L., Horwitz L. J., Blaauw A., Khorana S., Tucker S., Woods T., Warmuth M., Dicke K. A., McCredie K. B., Spitzer G. Evaluation of drugs for elimination of leukemic cells from the bone marrow of patients with acute leukemia. Blood. 1988 Jan;71(1):166–172. [PubMed] [Google Scholar]
  3. Barletta C., Pelicci P. G., Kenyon L. C., Smith S. D., Dalla-Favera R. Relationship between the c-myb locus and the 6q-chromosomal aberration in leukemias and lymphomas. Science. 1987 Feb 27;235(4792):1064–1067. doi: 10.1126/science.3469751. [DOI] [PubMed] [Google Scholar]
  4. Biedenkapp H., Borgmeyer U., Sippel A. E., Klempnauer K. H. Viral myb oncogene encodes a sequence-specific DNA-binding activity. Nature. 1988 Oct 27;335(6193):835–837. doi: 10.1038/335835a0. [DOI] [PubMed] [Google Scholar]
  5. Boyle W. J., Lampert M. A., Lipsick J. S., Baluda M. A. Avian myeloblastosis virus and E26 virus oncogene products are nuclear proteins. Proc Natl Acad Sci U S A. 1984 Jul;81(14):4265–4269. doi: 10.1073/pnas.81.14.4265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Calabretta B., Venturelli D., Kaczmarek L., Narni F., Talpaz M., Anderson B., Beran M., Baserga R. Altered expression of G1-specific genes in human malignant myeloid cells. Proc Natl Acad Sci U S A. 1986 Mar;83(5):1495–1498. doi: 10.1073/pnas.83.5.1495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Caracciolo D., Valtieri M., Venturelli D., Peschle C., Gewirtz A. M., Calabretta B. Lineage-specific requirement of c-abl function in normal hematopoiesis. Science. 1989 Sep 8;245(4922):1107–1110. doi: 10.1126/science.2672339. [DOI] [PubMed] [Google Scholar]
  8. Caracciolo D., Venturelli D., Valtieri M., Peschle C., Gewirtz A. M., Calabretta B. Stage-related proliferative activity determines c-myb functional requirements during normal human hematopoiesis. J Clin Invest. 1990 Jan;85(1):55–61. doi: 10.1172/JCI114433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Champlin R., Gale R. P. Acute myelogenous leukemia: recent advances in therapy. Blood. 1987 Jun;69(6):1551–1562. [PubMed] [Google Scholar]
  10. Clarke M. F., Kukowska-Latallo J. F., Westin E., Smith M., Prochownik E. V. Constitutive expression of a c-myb cDNA blocks Friend murine erythroleukemia cell differentiation. Mol Cell Biol. 1988 Feb;8(2):884–892. doi: 10.1128/mcb.8.2.884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Duprey S. P., Boettiger D. Developmental regulation of c-myb in normal myeloid progenitor cells. Proc Natl Acad Sci U S A. 1985 Oct;82(20):6937–6941. doi: 10.1073/pnas.82.20.6937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gewirtz A. M., Anfossi G., Venturelli D., Valpreda S., Sims R., Calabretta B. G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb. Science. 1989 Jul 14;245(4914):180–183. doi: 10.1126/science.2665077. [DOI] [PubMed] [Google Scholar]
  13. Gewirtz A. M., Calabretta B. A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science. 1988 Dec 2;242(4883):1303–1306. doi: 10.1126/science.2461588. [DOI] [PubMed] [Google Scholar]
  14. Gewirtz A. M., Xu W. Y., Mangan K. F. Role of natural killer cells, in comparison with T lymphocytes and monocytes, in the regulation of normal human megakaryocytopoiesis in vitro. J Immunol. 1987 Nov 1;139(9):2915–2924. [PubMed] [Google Scholar]
  15. Gonda T. J., Metcalf D. Expression of myb, myc and fos proto-oncogenes during the differentiation of a murine myeloid leukaemia. Nature. 1984 Jul 19;310(5974):249–251. doi: 10.1038/310249a0. [DOI] [PubMed] [Google Scholar]
  16. Hoelzer D., Gale R. P. Acute lymphoblastic leukemia in adults: recent progress, future directions. Semin Hematol. 1987 Jan;24(1):27–39. [PubMed] [Google Scholar]
  17. Kastan M. B., Stone K. D., Civin C. I. Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells. Blood. 1989 Oct;74(5):1517–1524. [PubMed] [Google Scholar]
  18. Klempnauer K. H., Symonds G., Evan G. I., Bishop J. M. Subcellular localization of proteins encoded by oncogenes of avian myeloblastosis virus and avian leukemia virus E26 and by chicken c-myb gene. Cell. 1984 Jun;37(2):537–547. doi: 10.1016/0092-8674(84)90384-2. [DOI] [PubMed] [Google Scholar]
  19. Lithotripsy. Health and Public Policy Committee, American College of Physicians. Ann Intern Med. 1985 Oct;103(4):626–629. [PubMed] [Google Scholar]
  20. Majello B., Kenyon L. C., Dalla-Favera R. Human c-myb protooncogene: nucleotide sequence of cDNA and organization of the genomic locus. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9636–9640. doi: 10.1073/pnas.83.24.9636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ness S. A., Marknell A., Graf T. The v-myb oncogene product binds to and activates the promyelocyte-specific mim-1 gene. Cell. 1989 Dec 22;59(6):1115–1125. doi: 10.1016/0092-8674(89)90767-8. [DOI] [PubMed] [Google Scholar]
  22. Ramsay R. G., Ikeda K., Rifkind R. A., Marks P. A. Changes in gene expression associated with induced differentiation of erythroleukemia: protooncogenes, globin genes, and cell division. Proc Natl Acad Sci U S A. 1986 Sep;83(18):6849–6853. doi: 10.1073/pnas.83.18.6849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Shtivelman E., Lifshitz B., Gale R. P., Roe B. A., Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell. 1986 Oct 24;47(2):277–284. doi: 10.1016/0092-8674(86)90450-2. [DOI] [PubMed] [Google Scholar]
  24. Slamon D. J., Boone T. C., Murdock D. C., Keith D. E., Press M. F., Larson R. A., Souza L. M. Studies of the human c-myb gene and its product in human acute leukemias. Science. 1986 Jul 18;233(4761):347–351. doi: 10.1126/science.3014652. [DOI] [PubMed] [Google Scholar]
  25. Slamon D. J. Proto-oncogenes and human cancers. N Engl J Med. 1987 Oct 8;317(15):955–957. doi: 10.1056/NEJM198710083171509. [DOI] [PubMed] [Google Scholar]
  26. Spitzer G., Verma D. S., Fisher R., Zander A., Vellekoop L., Litam J., McCredie K. B., Dicke K. A. The myeloid progenitor cell--its value in predicting hematopoietic recovery after autologous bone marrow transplantation. Blood. 1980 Feb;55(2):317–323. [PubMed] [Google Scholar]
  27. Todokoro K., Watson R. J., Higo H., Amanuma H., Kuramochi S., Yanagisawa H., Ikawa Y. Down-regulation of c-myb gene expression is a prerequisite for erythropoietin-induced erythroid differentiation. Proc Natl Acad Sci U S A. 1988 Dec;85(23):8900–8904. doi: 10.1073/pnas.85.23.8900. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Westin E. H., Gallo R. C., Arya S. K., Eva A., Souza L. M., Baluda M. A., Aaronson S. A., Wong-Staal F. Differential expression of the amv gene in human hematopoietic cells. Proc Natl Acad Sci U S A. 1982 Apr;79(7):2194–2198. doi: 10.1073/pnas.79.7.2194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. van der Krol A. R., Mol J. N., Stuitje A. R. Modulation of eukaryotic gene expression by complementary RNA or DNA sequences. Biotechniques. 1988 Nov-Dec;6(10):958–976. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES